Targeting a cure in anaplastic lymphoma kinase-positive non-small cell lung cancer
Open Access
- 1 December 2024
- journal article
- editorial
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 13 (12) , 3815-3818
Abstract
Targeting a cure in anaplastic lymphoma kinase-positive non-small cell lung cancerKeywords
This publication has 17 references indexed in Scilit:
- Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitorsCancer Medicine, 2022
- Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCJournal of Thoracic Oncology, 2021
- Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2020
- Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK InhibitorsJournal of Thoracic Oncology, 2020
- Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation DiversityClinical Cancer Research, 2019
- Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung CancerJournal of Thoracic Oncology, 2019
- ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2019
- Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III TrialJournal of Clinical Oncology, 2015
- Patients’ and doctors’ preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: What makes it worthwhile?European Journal of Cancer, 2015
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008